Yuan Zhou1, Hong-Gang Jiang, Ning Lu, Bo-Hao Lu, Zhi-Heng Chen. 1. Department of surgical oncology, Shanghai Jiao Tong University Affiliated First People's Hospital Jiaxing Branch, Jiaxing First Hospital, Jiaxing, Zhejiang, China E-mail : yuan8422@163.com.
Abstract
PURPOSE: To investigate the expression of Ki67 protein in papillary thyroid microcarcinoma(PTMC), and to analyze its clinical significance. MATERIALS AND METHODS: Ki67 protein expression was evaluated in the tissues of 108 human PTMC and 50 other benign papillary hyperplasia of thyroid specimens using immunohistochemistry. RESULTS: The expression intensity of Ki67 in PTMC and benign papillary hyperplasia of thyroid specimens were 1.45±1.83% and 0.46±0.46%.The positive expression rates were 46.3% and 14%. There were significant differences between these two groups (p<0.01). There was no significant variation of the expression intensity and positive expression rates of Ki67 in PTMC with gender, age, position of the tumor and the level of TSH pre-operation (p>0.05), but these parameters varied with tumor size, invasion by membrane and cervical lymph node metastasis (p<0.05 or p<0.01). CONCLUSIONS: The expression of Ki67 in PTMC was related to tumor size, invasion by membrane and cervical lymph node metastasis, and could be the important indicator for judging clinical progress and estimating prognosis.
PURPOSE: To investigate the expression of Ki67 protein in papillary thyroid microcarcinoma(PTMC), and to analyze its clinical significance. MATERIALS AND METHODS:Ki67 protein expression was evaluated in the tissues of 108 humanPTMC and 50 other benign papillary hyperplasia of thyroid specimens using immunohistochemistry. RESULTS: The expression intensity of Ki67 in PTMC and benign papillary hyperplasia of thyroid specimens were 1.45±1.83% and 0.46±0.46%.The positive expression rates were 46.3% and 14%. There were significant differences between these two groups (p<0.01). There was no significant variation of the expression intensity and positive expression rates of Ki67 in PTMC with gender, age, position of the tumor and the level of TSH pre-operation (p>0.05), but these parameters varied with tumor size, invasion by membrane and cervical lymph node metastasis (p<0.05 or p<0.01). CONCLUSIONS: The expression of Ki67 in PTMC was related to tumor size, invasion by membrane and cervical lymph node metastasis, and could be the important indicator for judging clinical progress and estimating prognosis.
Authors: Dilmi Perera; Ronald Ghossein; Niedzica Camacho; Yasin Senbabaoglu; Venkatraman Seshan; Juan Li; Nancy Bouvier; Laura Boucai; Agnes Viale; Nicholas D Socci; Brian R Untch; Mithat Gonen; Jeffrey Knauf; James A Fagin; Michael Berger; R Michael Tuttle Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 6.134